<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02845297</url>
  </required_header>
  <id_info>
    <org_study_id>J1651</org_study_id>
    <secondary_id>IRB00098812</secondary_id>
    <nct_id>NCT02845297</nct_id>
  </id_info>
  <brief_title>Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients</brief_title>
  <official_title>Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, nonrandomized, open-label phase 2 study (with a safety run-in phase)&#xD;
      of azacitidine (AZA) 75 mg/m2 given IV or SQ on days 1-7 every 28 days in combination with&#xD;
      pembrolizumab 200 mg given IV every 3 weeks (starting on day 8 of cycle 1). The dose/schedule&#xD;
      of AZA selected for this study is FDA approved for patients with MDS/AML.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Actual">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximal tolerable dose of AZA followed by pembrolizumab</measure>
    <time_frame>3- 28 day cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the complete remission (CR/CRi) rate of AZA followed by pembrolizumab.</measure>
    <time_frame>3-28 day cycles</time_frame>
    <description>Response will be assessed using the International European LeukemiaNet Guidelines in AML63 and IWG Modified Response Criteria (2006)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Safety Run In Phase (only Cohort 1):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment of relapsed and refractory AML patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The treatment of newly diagnosed AML patients (≥ 65 years) who are not candidates for intensive induction chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Intravenous pembrolizumab</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Safety Run In Phase (only Cohort 1):</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitadine</intervention_name>
    <description>Intravenous or subcutaneous</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Safety Run In Phase (only Cohort 1):</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Cohort #1&#xD;
&#xD;
          1. Have histologically or cytologically confirmed relapsed or refractory AML (i.e. ≥5%&#xD;
             blasts by manual differential on bone marrow aspirate/biopsy/flow cytometry),&#xD;
             excluding acute promyelocytic leukemia (APL; FAB M3; t(15;17))&#xD;
&#xD;
          2. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          3. Be &gt; 18 years of age on day of signing informed consent.&#xD;
&#xD;
          4. Not be appropriate candidate for intensive salvage chemotherapy due to co-morbidities&#xD;
             or other disease- or treatment-related factors.&#xD;
&#xD;
             NOTE: Subjects who received prior treatment with hypomethylating agents either for&#xD;
             Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasm (MPN), or AML will be&#xD;
             eligible if they achieved response to hypomethylating agents in the past (PR or CR)&#xD;
             and did not progress while receiving therapy with hypomethylating agents.&#xD;
&#xD;
             NOTE: Subjects who had prior allogeneic stem cell transplant (alloHSCT) will be&#xD;
             eligible as long as they have been at least 3 months after allogeneic HSCT and are off&#xD;
             of all immune suppression for at least 3 weeks (&gt;21 days) and have no evidence of&#xD;
             active graft versus host disease (GVHD). Subjects with prior alloHSCT will NOT be&#xD;
             eligible for enrollment during the safety run in phase.&#xD;
&#xD;
          5. Demonstrate adequate organ function as defined in Table 1, all screening labs should&#xD;
             be performed within 14 days of treatment initiation.&#xD;
&#xD;
          6. ECOG performance status ≤ 2.&#xD;
&#xD;
          7. A projected life expectancy of at least 12 weeks.&#xD;
&#xD;
          8. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
          9. Female subjects of childbearing potential (Section 5.8.2) must be willing to use an&#xD;
             adequate method of contraception as outlined in Section 5.8.2 - Contraception, for the&#xD;
             course of the study through 120 days after the last dose of study medication.&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
             contraception for the subject.&#xD;
&#xD;
         10. Male subjects of childbearing potential (Section 5.8.2) must agree to use an adequate&#xD;
             method of contraception as outlined in Section 5.8.2- Contraception, starting with the&#xD;
             first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
             contraception for the subject.&#xD;
&#xD;
         11. As determined by the enrolling physician or protocol designee, ability of the patient&#xD;
             to understand and comply with study procedures for the entire length of the study.&#xD;
&#xD;
        Cohort #2&#xD;
&#xD;
          1. Have histologically and cytologically confirmed newly diagnosed AML (i.e. ≥ 20% blasts&#xD;
             by manual differential on bone marrow aspirate/biopsy and/or in peripheral blood),&#xD;
             excluding acute promyelocytic leukemia (APL; FAB M3, t (15;17))&#xD;
&#xD;
          2. Be willing and able to provide written informed consent/assent for the trial.&#xD;
&#xD;
          3. Be ≥65 years of age on day of signing informed consent.&#xD;
&#xD;
          4. Have received NO prior treatment for AML with the exception of&#xD;
             hydroxyurea/leukapheresis.&#xD;
&#xD;
             NOTE: Subjects may have been treated for pre-existent myeloid disorder such as&#xD;
             Myelodysplastic Syndrome or Myeloproliferative Neoplasm excluding hypomethylating&#xD;
             agents.&#xD;
&#xD;
          5. Demonstrate adequate organ function as defined in Table 1, all screening labs should&#xD;
             be performed within 14 days of treatment initiation.&#xD;
&#xD;
          6. ECOG performance status ≤ 2.&#xD;
&#xD;
          7. A projected life expectancy of at least 12 weeks.&#xD;
&#xD;
          8. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy within 72 hours prior to receiving the first dose of study medication. If&#xD;
             the urine test is positive or cannot be confirmed as negative, a serum pregnancy test&#xD;
             will be required.&#xD;
&#xD;
          9. Female subjects of childbearing potential (Section 5.8.2) must be willing to use an&#xD;
             adequate method of contraception as outlined in Section 5.8.2 - Contraception, for the&#xD;
             course of the study through 120 days after the last dose of study medication.&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
             contraception for the subject.&#xD;
&#xD;
         10. Male subjects of childbearing potential (Section 5.8.2) must agree to use an adequate&#xD;
             method of contraception as outlined in Section 5.8.2- Contraception, starting with the&#xD;
             first dose of study therapy through 120 days after the last dose of study therapy.&#xD;
&#xD;
             Note: Abstinence is acceptable if this is the usual lifestyle and preferred&#xD;
             contraception for the subject.&#xD;
&#xD;
         11. As determined by the enrolling physician or protocol designee, ability of the patient&#xD;
             to understand and comply with study procedures for the entire length of the study.&#xD;
&#xD;
        Adequate Organ Function Laboratory Values&#xD;
&#xD;
        White blood cell (WBC) count &lt;30,000 /mcL&#xD;
&#xD;
        Serum creatinine OR Measured or calculated creatinine clearance (GFR can also be used in&#xD;
        place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR ≥60 mL/min for subject&#xD;
        with creatinine levels &gt; 1.5 X institutional ULN Serum total bilirubin ≤ 1.5 X ULN* AST&#xD;
        (SGOT) and ALT (SGPT) ≤ 3 X ULN Albumin &gt;2.5 mg/dL International Normalized Ratio (INR) or&#xD;
        Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless&#xD;
        subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range&#xD;
        of intended use of anticoagulants&#xD;
&#xD;
        ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within&#xD;
        therapeutic range of intended use of anticoagulants&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Cohort #1&#xD;
&#xD;
          1. Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks of the first dose of treatment.&#xD;
&#xD;
             NOTE: Subjects who were treated on a clinical study of allogeneic stem cell transplant&#xD;
             (alloHSCT) will be eligible if they are at least 3 months after allogeneic HCT and are&#xD;
             at least 3 weeks (&gt;21 days) off of all immune suppression and have no evidence of&#xD;
             active GVHD (physiologic corticosteroid replacement therapy for adrenal or pituitary&#xD;
             insufficiency is allowed). Subjects with prior alloHSCT will not be eligible for&#xD;
             enrollment during the safety run in phase.&#xD;
&#xD;
          2. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          3. Has a known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
          4. Hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          5. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study&#xD;
             Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events&#xD;
             due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
          6. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy&#xD;
             within 2 weeks or growth factors within 1 week prior to study Day 1 or who has not&#xD;
             recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously&#xD;
             administered agent.&#xD;
&#xD;
               -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and&#xD;
                  may qualify for the study.&#xD;
&#xD;
               -  Note: If subject received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy.&#xD;
&#xD;
          7. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
          8. Has known active central nervous system (CNS) leukemia. Subjects with previously&#xD;
             treated CNS leukemia may participate provided that they have documented clearance of&#xD;
             CNS leukemia and are not actively treated with intrathecal chemotherapy.&#xD;
&#xD;
          9. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment. Subjects that require intermittent use of bronchodilators&#xD;
             or local steroid injections will not be excluded from the study.&#xD;
&#xD;
         10. Has known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
         11. Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or&#xD;
             fungal). Patients with infection under active treatment and controlled with&#xD;
             antibiotics are eligible.&#xD;
&#xD;
         12. Has a white blood cell count &gt; 30 x 109/L. NOTE: Leukapheresis and Hydroxyurea is&#xD;
             permitted to meet this criterion and should be stopped ≥12 hours before starting&#xD;
             treatment on the study.&#xD;
&#xD;
         13. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         14. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         15. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         16. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
         17. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         18. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         19. Has received a live vaccine within 30 days of planned start of study therapy. Note:&#xD;
             Seasonal influenza vaccines for injection are generally inactivated flu vaccines and&#xD;
             are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live&#xD;
             attenuated vaccines, and are not allowed.&#xD;
&#xD;
        Cohort #2&#xD;
&#xD;
          1. Has received treatment with hypomethylating agent for pre-existent myeloid disorder&#xD;
             such Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasm (MPN).&#xD;
&#xD;
          2. Is currently participating and receiving study therapy or has participated in a study&#xD;
             of an investigational agent and received study therapy or used an investigational&#xD;
             device within 4 weeks of the first dose of treatment for pre-existent myeloid disorder&#xD;
             such as MDS or MPN.&#xD;
&#xD;
          3. Not be eligible for treatment with a standard cytarabine and anthracycline or similar&#xD;
             intensive induction chemotherapy due to co-morbidities or other factors, or is&#xD;
             unwilling to receive intensive induction therapy.&#xD;
&#xD;
          4. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any&#xD;
             other form of immunosuppressive therapy within 7 days prior to the first dose of trial&#xD;
             treatment.&#xD;
&#xD;
          5. Has a known history of active TB (Bacillus Tuberculosis)&#xD;
&#xD;
          6. Hypersensitivity to pembrolizumab or any of its excipients.&#xD;
&#xD;
          7. Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study&#xD;
             Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events&#xD;
             due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
          8. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy&#xD;
             within 2 weeks or growth factors within 1 week prior to study Day 1 or who has not&#xD;
             recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously&#xD;
             administered agent.&#xD;
&#xD;
               -  Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and&#xD;
                  may qualify for the study.&#xD;
&#xD;
               -  Note: If subject received major surgery, they must have recovered adequately from&#xD;
                  the toxicity and/or complications from the intervention prior to starting&#xD;
                  therapy.&#xD;
&#xD;
          9. Has a known additional malignancy that is progressing or requires active treatment.&#xD;
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the&#xD;
             skin that has undergone potentially curative therapy or in situ cervical cancer.&#xD;
&#xD;
         10. Has known active central nervous system (CNS) leukemia. Subjects with previously&#xD;
             treated CNS leukemia may participate provided that they have documented clearance of&#xD;
             CNS leukemia and are not actively treated with intrathecal chemotherapy.&#xD;
&#xD;
         11. Has active autoimmune disease that has required systemic treatment in the past 2 years&#xD;
             (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a&#xD;
             form of systemic treatment. Subjects that require intermittent use of bronchodilators&#xD;
             or local steroid injections will not be excluded from the study.&#xD;
&#xD;
         12. Has known history of, or any evidence of active, non-infectious pneumonitis.&#xD;
&#xD;
         13. Has an active uncontrolled infection requiring systemic therapy (viral, bacterial or&#xD;
             fungal). Patients with infection under active treatment and controlled with&#xD;
             antibiotics are eligible.&#xD;
&#xD;
         14. Has a white blood cell count &gt; 30 x 109/L. NOTE: Leukapheresis and hydroxyurea is&#xD;
             permitted to meet this criterion and should be stopped ≥12 hours before starting&#xD;
             treatment on the study.&#xD;
&#xD;
         15. Has a history or current evidence of any condition, therapy, or laboratory abnormality&#xD;
             that might confound the results of the trial, interfere with the subject's&#xD;
             participation for the full duration of the trial, or is not in the best interest of&#xD;
             the subject to participate, in the opinion of the treating investigator.&#xD;
&#xD;
         16. Has known psychiatric or substance abuse disorders that would interfere with&#xD;
             cooperation with the requirements of the trial.&#xD;
&#xD;
         17. Is pregnant or breastfeeding, or expecting to conceive or father children within the&#xD;
             projected duration of the trial, starting with the pre-screening or screening visit&#xD;
             through 120 days after the last dose of trial treatment.&#xD;
&#xD;
         18. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.&#xD;
&#xD;
         19. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).&#xD;
&#xD;
         20. Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA&#xD;
             [qualitative] is detected).&#xD;
&#xD;
         21. Has received a live vaccine within 30 days of planned start of study therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivana Gojo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

